JP2002507600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002507600A5 JP2002507600A5 JP2000537853A JP2000537853A JP2002507600A5 JP 2002507600 A5 JP2002507600 A5 JP 2002507600A5 JP 2000537853 A JP2000537853 A JP 2000537853A JP 2000537853 A JP2000537853 A JP 2000537853A JP 2002507600 A5 JP2002507600 A5 JP 2002507600A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- embedded image
- compound
- here
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC([C@](*)CC(CCC1)CN1C(N)=N)NC(c(cc1)ccc1-c1ccccc1)=O Chemical compound CC([C@](*)CC(CCC1)CN1C(N)=N)NC(c(cc1)ccc1-c1ccccc1)=O 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- -1 phenyl-substituted phenyl Chemical group 0.000 description 4
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
- 125000001072 heteroaryl group Chemical class 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 description 1
- YALBSZKTUKJWQM-UHFFFAOYSA-N 1-N,1-N-diethyl-2-N,2-N',2-N'-trimethylpyrrolidine-1,2,2,3-tetramine Chemical compound NC1C(N(CC1)N(CC)CC)(N(C)C)NC YALBSZKTUKJWQM-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- JJFLDHBSMPNEPU-IVAFLUGOSA-N CC([C@@H](CC(CC1)=CCN1C(N)=N)C(OC)=O)NC(c(cc1)ccc1-c1ccccc1)=O Chemical compound CC([C@@H](CC(CC1)=CCN1C(N)=N)C(OC)=O)NC(c(cc1)ccc1-c1ccccc1)=O JJFLDHBSMPNEPU-IVAFLUGOSA-N 0.000 description 1
- CLYMUWFQNFEMJT-IVAFLUGOSA-N CC([C@@H](CC1CCNCC1)C(OC)=O)NC(c(cc1)ccc1-c1ccccc1)=O Chemical compound CC([C@@H](CC1CCNCC1)C(OC)=O)NC(c(cc1)ccc1-c1ccccc1)=O CLYMUWFQNFEMJT-IVAFLUGOSA-N 0.000 description 1
- FSAURURHTUEOLY-PAHOBDAQSA-N CCC([C@@H](CC(CCC1)CN1C(N)=N)C(OC)=O)NC(c(cc1)ccc1-c1cc(CN)ccc1)=O Chemical compound CCC([C@@H](CC(CCC1)CN1C(N)=N)C(OC)=O)NC(c(cc1)ccc1-c1cc(CN)ccc1)=O FSAURURHTUEOLY-PAHOBDAQSA-N 0.000 description 1
- MQCUMGNIFMPZGY-FQLXRVMXSA-N COC([C@H](CCC1CCNCC1)[C@@H](CCc1ccccc1)NC(c(cc1)ccc1C1=CC=CNC1)=O)=O Chemical compound COC([C@H](CCC1CCNCC1)[C@@H](CCc1ccccc1)NC(c(cc1)ccc1C1=CC=CNC1)=O)=O MQCUMGNIFMPZGY-FQLXRVMXSA-N 0.000 description 1
- GLFPUJSRGLHTNJ-KCUXUGRMSA-N COC([C@H](CCCC1CCNCC1)[C@@H](CCc1ccccc1)NC(c(cc1)ccc1-c1cccnc1)O)=O Chemical compound COC([C@H](CCCC1CCNCC1)[C@@H](CCc1ccccc1)NC(c(cc1)ccc1-c1cccnc1)O)=O GLFPUJSRGLHTNJ-KCUXUGRMSA-N 0.000 description 1
- FQJFKKBSQSSURN-RMRANGLJSA-N C[C@H]([C@@H](CC1CNCCC1)C(OC)=O)NC(c(cc1)ccc1-c1ncccc1)=O Chemical compound C[C@H]([C@@H](CC1CNCCC1)C(OC)=O)NC(c(cc1)ccc1-c1ncccc1)=O FQJFKKBSQSSURN-RMRANGLJSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000005542 phthalazyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7900298P | 1998-03-23 | 1998-03-23 | |
| US60/079,002 | 1998-03-23 | ||
| PCT/US1999/006224 WO1999048870A1 (en) | 1998-03-23 | 1999-03-22 | Piperididinyl and n-amidinopiperidinyl derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002507600A JP2002507600A (ja) | 2002-03-12 |
| JP2002507600A5 true JP2002507600A5 (https=) | 2006-05-18 |
| JP4495339B2 JP4495339B2 (ja) | 2010-07-07 |
Family
ID=22147579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000537853A Expired - Fee Related JP4495339B2 (ja) | 1998-03-23 | 1999-03-22 | ピペリジニルおよびｎ−アミジノピペリジニル誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6277865B1 (https=) |
| EP (1) | EP1080075B1 (https=) |
| JP (1) | JP4495339B2 (https=) |
| KR (1) | KR20010042125A (https=) |
| CN (1) | CN1297440A (https=) |
| AT (1) | ATE273277T1 (https=) |
| AU (1) | AU757868B2 (https=) |
| BR (1) | BR9909086A (https=) |
| CA (1) | CA2325471C (https=) |
| DE (1) | DE69919349T2 (https=) |
| ES (1) | ES2224620T3 (https=) |
| HU (1) | HUP0101482A3 (https=) |
| PL (1) | PL344056A1 (https=) |
| TR (1) | TR200002740T2 (https=) |
| WO (1) | WO1999048870A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL362320A1 (en) * | 2000-12-06 | 2004-10-18 | Aventis Pharma Deutschland Gmbh | Guanidine and amidine derivatives as factor xa inhibitors |
| DE10124041A1 (de) * | 2001-05-16 | 2002-11-21 | Graffinity Pharm Design Gmbh | Protease Inhibitoren |
| AU2003302238A1 (en) | 2002-12-03 | 2004-06-23 | Axys Pharmaceuticals, Inc. | 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors |
| PL3357911T3 (pl) | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| NO2686520T3 (https=) | 2011-06-06 | 2018-03-17 | ||
| WO2012170439A1 (en) | 2011-06-06 | 2012-12-13 | The Ohio State University | Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer |
| EP2759533B1 (en) | 2011-09-22 | 2017-08-02 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| JP2016521747A (ja) | 2013-06-13 | 2016-07-25 | アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 貧血治療のための組成物及び方法 |
| MY180626A (en) | 2013-11-15 | 2020-12-03 | Akebia Therapeutics Inc | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
| US10150734B2 (en) | 2015-01-23 | 2018-12-11 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| US11324734B2 (en) | 2015-04-01 | 2022-05-10 | Akebia Therapeutics, Inc. | Compositions and methods for treating anemia |
| US11713298B2 (en) | 2018-05-09 | 2023-08-01 | Akebia Therapeutics, Inc. | Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid |
| US11524939B2 (en) | 2019-11-13 | 2022-12-13 | Akebia Therapeutics, Inc. | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid |
| WO2021117767A1 (ja) | 2019-12-10 | 2021-06-17 | 田辺三菱製薬株式会社 | 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916145A (en) * | 1987-07-10 | 1990-04-10 | Hoffmann-La Roche Inc. | Substituted n-[(pyridyl)alkyl]aryl-carboxamide |
| GB9107043D0 (en) * | 1991-04-04 | 1991-05-22 | Pfizer Ltd | Therapeutic agents |
| JPH08504194A (ja) * | 1992-12-01 | 1996-05-07 | メルク エンド カンパニー インコーポレーテッド | フィブリノーゲンレセプターアンタゴニスト |
| US5583146A (en) * | 1992-12-02 | 1996-12-10 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
| DE4337611A1 (de) * | 1993-11-04 | 1995-05-11 | Boehringer Ingelheim Kg | Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| US5658930A (en) * | 1994-12-13 | 1997-08-19 | Corvas International, Inc. | Aromatic heterocyclic derivatives as enzyme inhibitors |
| MX9704439A (es) * | 1994-12-13 | 1997-10-31 | Corvas Int Inc | Derivados heterociclicos aromaticos como inhibidores de enzima. |
| DE19502644A1 (de) * | 1995-01-28 | 1996-08-01 | Merck Patent Gmbh | 4-Amino-benzoylguanidin-Derivate |
| CA2233344A1 (en) * | 1995-09-29 | 1997-04-03 | 3-Dimensional Pharmaceuticals, Inc. | Guanidino protease inhibitors |
| US5852045A (en) * | 1995-10-19 | 1998-12-22 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| EP0866705A4 (en) * | 1995-10-19 | 1999-03-03 | Merck & Co Inc | FIBRINOGENIC RECEPTOR ANTAGONISTS |
| AU723338B2 (en) * | 1996-01-02 | 2000-08-24 | Aventis Pharmaceuticals Inc. | Substituted n-{(aminoiminomethyl or aminomethyl)phenyl}propyl amides |
| US5668289A (en) | 1996-06-24 | 1997-09-16 | Merck & Co., Inc. | Pyridinone thrombin inhibitors |
-
1999
- 1999-03-22 EP EP99912798A patent/EP1080075B1/en not_active Expired - Lifetime
- 1999-03-22 WO PCT/US1999/006224 patent/WO1999048870A1/en not_active Ceased
- 1999-03-22 KR KR1020007010524A patent/KR20010042125A/ko not_active Withdrawn
- 1999-03-22 PL PL99344056A patent/PL344056A1/xx unknown
- 1999-03-22 HU HU0101482A patent/HUP0101482A3/hu unknown
- 1999-03-22 AU AU31094/99A patent/AU757868B2/en not_active Ceased
- 1999-03-22 TR TR2000/02740T patent/TR200002740T2/xx unknown
- 1999-03-22 DE DE1999619349 patent/DE69919349T2/de not_active Expired - Lifetime
- 1999-03-22 ES ES99912798T patent/ES2224620T3/es not_active Expired - Lifetime
- 1999-03-22 CN CN99805060A patent/CN1297440A/zh active Pending
- 1999-03-22 BR BR9909086-4A patent/BR9909086A/pt not_active IP Right Cessation
- 1999-03-22 AT AT99912798T patent/ATE273277T1/de not_active IP Right Cessation
- 1999-03-22 CA CA2325471A patent/CA2325471C/en not_active Expired - Fee Related
- 1999-03-22 JP JP2000537853A patent/JP4495339B2/ja not_active Expired - Fee Related
- 1999-03-22 US US09/273,618 patent/US6277865B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002507600A5 (https=) | ||
| JP2007513915A5 (https=) | ||
| CA2336952A1 (en) | 5-thia-.omega.-substituted phenyl-prostaglandin e derivatives, process for producing the same and drugs containing the same as the active ingredient | |
| KR960704851A (ko) | 면역억제제로서 유용한 카보사이클과 헤테로사이클이 융합된-고리 퀴놀린카복실산 (carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents) | |
| CA2413313A1 (en) | Antitumor effect potentiators | |
| JP2021519766A (ja) | ＸＩＩａ因子インヒビター | |
| RU2002129354A (ru) | Производные этилендиамина | |
| JP2005501120A5 (https=) | ||
| JP2004531517A5 (https=) | ||
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| JP2007511487A5 (https=) | ||
| CA2597069A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| JP2021523887A (ja) | ＸＩＩａ因子インヒビター | |
| HUE034869T2 (en) | Combination therapy with substituted oxazolidinones | |
| KR20170055531A (ko) | 에스지씨 자극제 | |
| JP2009521472A (ja) | 心肺手術の合併症の予防としてのトロンビンレセプターアンタゴニスト | |
| EP0682947B1 (en) | Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia | |
| KR940702491A (ko) | 옥사졸리돈 유도체 | |
| JP2003522768A5 (https=) | ||
| JP2003535890A (ja) | アクリロイルジスタマイシン誘導体並びにトポイソメラーゼｉ及びｉｉ阻害剤を含む薬剤組成物 | |
| JP4175887B2 (ja) | 新規血管狭窄治療剤または予防剤 | |
| JP2000103736A (ja) | 血管透過性亢進抑制剤 | |
| JP2838282B2 (ja) | 血管攣縮治療剤 | |
| RS53896B1 (sr) | Pantenil dokosaheksaenoat i njegova upotreba za lečenje i prevenciju kardiovaskularnih oboljenja | |
| JPS63501360A (ja) | 血栓性および血栓塞栓性疾患の治療のためのプロスタサイクリン、その類縁体またはプロスタグランジンおよびトロンボキサン類縁体 |